NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-s

Bank of America Corp DE grew its stake in shares of Protara Therapeutics, Inc. (NASDAQ: TARA) by 86.

Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.36) per share which missed the a

Protara Therapeutics is rated Buy, with a risk-adjusted fair value of $9.96 per share versus the cur

Shares of Protara Therapeutics, Inc. (NASDAQ: TARA - Get Free Report) have received an average ratin

Protara Therapeutics (TARA) might move higher on growing optimism about its earnings prospects, whic

MIAMI, July 20, 2026 /PRNewswire/ -- Royal Caribbean Group (NYSE: RCL) today announced the appointme

NEW YORK--(BUSINESS WIRE)--Tradeweb Markets Inc. (Nasdaq: TW), a global leader in electronic trading

$100,000,000Common StockWe have entered into a sales agreement with TD Securities (USA) LLC, or TD C

Oppenheimer analyst Leland Gershell maintains Protara Therapeutics (NASDAQ:TARA) with a Outperfor

NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-sta

Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial

Event will provide an overview of Lymphatic Malformations, the treatment landscape and the TARA-002

Event will provide an overview of Lymphatic Malformations, the treatment landscape and the TARA-002

Protara Therapeutics Inc. (NASDAQ:TARA) reported updated 12-month Phase 2 data for TARA-002 in patie

Protara reports updated Phase 2 data showing durable responses and favorable safety for TARA-002 in

    TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the

TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the 6-mo

JP Morgan analyst Brian Cheng maintains Protara Therapeutics (NASDAQ:TARA) with a Overweight and

Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.31) per share which beat the ana

The Company intends to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malfor

HC Wainwright & Co. analyst Andrew S. Fein maintains Protara Therapeutics (NASDAQ:TARA) with

Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage biotechnology company developing transfor

NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-s

Protara Therapeutics, Inc. (NASDAQ: TARA - Get Free Report) was the recipient of a large increase in

Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.37) per share which missed the a

Reported interim data from ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC); TARA-002

JP Morgan analyst Brian Cheng initiates coverage on Protara Therapeutics (NASDAQ:TARA) with a Ove

Protara Therapeutics (NASDAQ: TARA) executives outlined progress across the company's two clinical-s

Protara Therapeutics, Inc. (TARA) Discusses Interim Phase II Results for TARA-002 in Non-Muscle Inva

Protara Therapeutics (TARA) shares down after release of interim results for TARA-002 treatment of N

Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse event

Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse event

NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-st

  On Tuesday, 647 companies set new 52-week lows.

  On Monday, 369 companies set new 52-week lows.

  Friday's session saw 169 companies set new 52-week lows.

  Monday's session saw 175 companies set new 52-week lows.

  Friday's session saw 225 companies set new 52-week lows.

  On Wednesday, 179 companies reached new 52-week lows.

  On Wednesday, 283 companies set new 52-week lows.

  On Wednesday, 807 companies reached new 52-week lows.